Get started
GSK plc Sponsored ADRGSK plc Sponsored ADRGSK plc Sponsored ADR

GSK plc Sponsored ADR

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsOptionsBondsETFs

Chart


Full chart

Key facts today


GSK's stock rose nearly 7% after a strong third quarter, with the company raising its 2025 profit forecast. Core earnings per share growth is now expected at 10% to 12%.
On October 31, 2025, GSK plc bought 7,128,500 shares, totaling 254,593,344 treasury shares. This represents 6.27% of the voting rights from 4,060,827,442 issued shares.
GSK contributed to the recent rally in the FTSE 100, which reached record highs this week, following the release of upbeat earnings results.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪94.22 B‬ USD
Dividend yield (indicated)
3.53%
Price to earnings Ratio (TTM)
13.10
Basic EPS (TTM)
3.56 USD
Net income (FY)
‪3.29 B‬ USD
Revenue (FY)
‪40.09 B‬ USD
Shares float
‪2.01 B‬
Beta (1Y)
0.32

About GSK plc


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Emma N. Walmsley
Website
gsk.com
Headquarters
London
ISIN
US37733W2044
FIGI
BBG000BLB481
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Check out other big names from the same industry as GSK.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


83GI
GlaxoSmithKline Capital Plc 5.25% 10-APR-2042
Yield to maturity
5.79%
Maturity date
Apr 10, 2042
17RI
GlaxoSmithKline Capital Plc 4.25% 18-DEC-2045
Yield to maturity
5.61%
Maturity date
Dec 18, 2045
71ZC
GlaxoSmithKline Capital Plc 6.375% 09-MAR-2039
Yield to maturity
5.29%
Maturity date
Mar 9, 2039
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
Yield to maturity
5.14%
Maturity date
Mar 18, 2043
XS217060907
GlaxoSmithKline Capital Plc 1.625% 12-MAY-2035
Yield to maturity
4.96%
Maturity date
May 12, 2035
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
Yield to maturity
4.96%
Maturity date
May 15, 2038
GSK6023693
GlaxoSmithKline Capital, Inc. 4.875% 15-APR-2035
Yield to maturity
4.69%
Maturity date
Apr 15, 2035
72WI
GlaxoSmithKline Capital, Inc. 5.375% 15-APR-2034
Yield to maturity
4.67%
Maturity date
Apr 15, 2034
AG99
GlaxoSmithKline Capital Plc 5.25% 19-DEC-2033
Yield to maturity
4.47%
Maturity date
Dec 19, 2033
GSK6023695
GlaxoSmithKline Capital, Inc. 4.5% 15-APR-2030
Yield to maturity
4.12%
Maturity date
Apr 15, 2030
US377373AH8
GlaxoSmithKline Capital Plc 3.375% 01-JUN-2029
Yield to maturity
4.09%
Maturity date
Jun 1, 2029

See all GSK bonds 

ETFs


PPH
VanEck Pharmaceutical ETF
Weight
4.97%
Market value
‪56.75 M‬
USD
AVDE
Avantis International Equity ETF
Weight
0.38%
Market value
‪39.78 M‬
USD
FVD
First Trust Value Line Dividend Index Fund
Weight
0.46%
Market value
‪39.23 M‬
USD
FENI
Fidelity Enhanced International ETF
Weight
0.60%
Market value
‪29.13 M‬
USD
FTHI
Fidelity Tactical High Income Fund Trust Units
Weight
0.26%
Market value
‪15.79 M‬
USD
RODM
Hartford Multifactor Developed Markets (ex-US) ETF
Weight
1.12%
Market value
‪14.13 M‬
USD
DFAX
Dimensional World ex U.S. Core Equity 2 ETF
Weight
0.11%
Market value
‪10.44 M‬
USD
AVIV
Avantis International Large Cap Value ETF
Weight
0.95%
Market value
‪8.65 M‬
USD
BINV
Brandes International ETF
Weight
2.71%
Market value
‪8.37 M‬
USD
FFLC
Fidelity Fundamental Large Cap Core ETF
Weight
0.85%
Market value
‪7.98 M‬
USD
PLDR
Putnam Sustainable Leaders ETF
Weight
0.78%
Market value
‪6.21 M‬
USD

Explore more ETFs 

Sparks


Curated watchlists where GSK is featured.

See all sparks